Cowen and Company reaffirmed their outperform rating on shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in a research note issued to investors on Wednesday. Cowen and Company currently has a $117.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $93.00.

A number of other brokerages have also recently commented on ALNY. Piper Jaffray Companies reaffirmed an overweight rating and issued a $116.00 price target (up from $110.00) on shares of Alnylam Pharmaceuticals in a research note on Wednesday. Needham & Company LLC upped their price target on Alnylam Pharmaceuticals from $85.00 to $125.00 and gave the company a buy rating in a research note on Wednesday. ValuEngine raised Alnylam Pharmaceuticals from a sell rating to a hold rating in a research note on Friday, September 1st. BMO Capital Markets reaffirmed an outperform rating and issued a $99.00 price target (down from $105.00) on shares of Alnylam Pharmaceuticals in a research note on Wednesday, September 6th. Finally, Barclays PLC reaffirmed an overweight rating and issued a $105.00 price target (up from $80.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, September 7th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and fourteen have issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average price target of $93.11.

Alnylam Pharmaceuticals (NASDAQ ALNY) opened at 113.80 on Wednesday. The stock’s market capitalization is $10.44 billion. The stock has a 50 day moving average of $81.14 and a 200 day moving average of $69.12. Alnylam Pharmaceuticals has a 52-week low of $31.38 and a 52-week high of $118.40.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.12). The company had revenue of $15.93 million during the quarter, compared to the consensus estimate of $23.86 million. Alnylam Pharmaceuticals had a negative net margin of 670.81% and a negative return on equity of 45.53%. The business’s revenue was up 82.9% compared to the same quarter last year. During the same period last year, the company earned ($1.05) earnings per share. On average, equities research analysts forecast that Alnylam Pharmaceuticals will post ($5.19) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Alnylam Pharmaceuticals, Inc. (ALNY) Rating Reiterated by Cowen and Company” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/09/24/alnylam-pharmaceuticals-inc-alny-rating-reiterated-by-cowen-and-company.html.

In other news, President Barry E. Greene sold 76,815 shares of the firm’s stock in a transaction that occurred on Wednesday, September 20th. The shares were sold at an average price of $100.00, for a total transaction of $7,681,500.00. Following the completion of the transaction, the president now directly owns 165,399 shares of the company’s stock, valued at approximately $16,539,900. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 4.30% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently modified their holdings of ALNY. BlackRock Inc. grew its stake in shares of Alnylam Pharmaceuticals by 34,755.2% during the 1st quarter. BlackRock Inc. now owns 4,746,234 shares of the biopharmaceutical company’s stock worth $243,242,000 after acquiring an additional 4,732,617 shares in the last quarter. Perceptive Advisors LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 831.4% in the 1st quarter. Perceptive Advisors LLC now owns 1,103,475 shares of the biopharmaceutical company’s stock valued at $56,553,000 after buying an additional 985,000 shares during the last quarter. FMR LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 6.3% in the 2nd quarter. FMR LLC now owns 13,723,153 shares of the biopharmaceutical company’s stock valued at $1,094,559,000 after buying an additional 815,270 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 13.4% in the 2nd quarter. Vanguard Group Inc. now owns 6,419,508 shares of the biopharmaceutical company’s stock valued at $512,020,000 after buying an additional 759,295 shares during the last quarter. Finally, Janus Henderson Group PLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $53,226,000. 94.25% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Stock Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.